If generic medicines are not available, treatment will become difficult for low and middle income patients, especially in diseases like TB, the importance of these medicines increases significantly. 

Generic Medicines For TB: TB has long been a serious public health challenge, especially in countries like India, which have historically carried a significant share of the global TB burden. However, the development of low-cost and availability of generic medicines are transforming TB treatment globally, raising hopes for more effective and accessible care.

The introduction and spread of generic drugs to treat TB

has revolutionised TB treatment globally. Dr Sujit Pal said that by providing cost-effective alternatives to patented drugs, generic drugs have made TB treatment more accessible, especially in low and middle-income countries. This increased access has led to an increase in treatment initiation rates, as financial barriers have been significantly reduced. In addition, the availability of affordable drugs has enabled national health programmes to allocate resources more efficiently, improving other aspects of TB care, such as diagnosis and patient support services.

Successes in India

India has made great progress in its fight against TB. According to the World Health Organization's Global TB Report 2024, the country's TB incidence rate has declined from 237 per 100,000 population in 2015 to 195 in 2023, representing a 17.7% reduction. This reduction is more than double the global average of 8.3% during the same period. In addition, India's TB mortality rate has declined from 28 per 100,000 population to 22 between 2015 and 2023. These achievements have put India on track to eliminate TB by the end of 2025, five years ahead of the global target set for 2030.

Production of generic medicines increased

India's pharmaceutical industry is producing a lot of generic TB medicines, which is making the treatment of this disease easier for the poor and middle class. Apart from TB, generic medicines are also proving to be very helpful in cancer and respiratory diseases.

Challenges ahead

Despite these progress, challenges remain in efforts to eliminate TB. Patent and licensing issues limit the availability of some generic drugs in specific regions, requiring continued advocacy for wider access. In addition, early and accurate diagnosis of TB is critical. Thus, investments in diagnostic techniques must be accompanied by availability of drugs to initiate timely treatment. Public awareness campaigns are also necessary to combat stigma and encourage people to seek timely care